Report for Shao F

General

Full name :

First name :

Mail :

Zip Code :

City :

Country :

Email :

Phone :

Fax :

Website :

Directory :

References (6)

Title : Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus - Zhou_2024_Front.Endocrinol.(Lausanne)_15_1359407
Author(s) : Zhou C , Zhou S , Wang J , Xie L , Lv Z , Zhao Y , Wang L , Luo H , Xie D , Shao F
Ref : Front Endocrinol (Lausanne) , 15 :1359407 , 2024
Abstract : Zhou_2024_Front.Endocrinol.(Lausanne)_15_1359407
ESTHER : Zhou_2024_Front.Endocrinol.(Lausanne)_15_1359407
PubMedSearch : Zhou_2024_Front.Endocrinol.(Lausanne)_15_1359407
PubMedID: 38529396

Title : A double-blind, randomized, placebo and positive-controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin - Lu_2022_Br.J.Clin.Pharmacol_88_2946
Author(s) : Lu J , Wang L , Zhou S , Zhou C , Xie L , Chen J , Tang D , Tian X , Xie D , Ding J , Wang T , Yu Q , Shao F
Ref : British Journal of Clinical Pharmacology , 88 :2946 , 2022
Abstract : Lu_2022_Br.J.Clin.Pharmacol_88_2946
ESTHER : Lu_2022_Br.J.Clin.Pharmacol_88_2946
PubMedSearch : Lu_2022_Br.J.Clin.Pharmacol_88_2946
PubMedID: 34965609

Title : First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus - Wang_2021_Clin.Drug.Investig_41_999
Author(s) : Wang L , Lu J , Zhou S , Zhao Y , Xie L , Zhou C , Chen J , Ding S , Xie D , Ding J , Yu Q , Shen H , Hao G , Shao F
Ref : Clin Drug Investig , 41 :999 , 2021
Abstract : Wang_2021_Clin.Drug.Investig_41_999
ESTHER : Wang_2021_Clin.Drug.Investig_41_999
PubMedSearch : Wang_2021_Clin.Drug.Investig_41_999
PubMedID: 34655432

Title : Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma - Zhang_2020_Front.Oncol_10_559568
Author(s) : Zhang H , Guo W , Zhang F , Li R , Zhou Y , Shao F , Feng X , Tan F , Wang J , Gao S , Gao Y , He J
Ref : Front Oncol , 10 :559568 , 2020
Abstract : Zhang_2020_Front.Oncol_10_559568
ESTHER : Zhang_2020_Front.Oncol_10_559568
PubMedSearch : Zhang_2020_Front.Oncol_10_559568
PubMedID: 33363004

Title : Galanthamine, an acetylcholine inhibitor, prevents prepulse inhibition deficits induced by adolescent social isolation or MK-801 treatment - Shao_2014_Brain.Res_1589_105
Author(s) : Shao S , Li M , Du W , Shao F , Wang W
Ref : Brain Research , 1589 :105 , 2014
Abstract : Shao_2014_Brain.Res_1589_105
ESTHER : Shao_2014_Brain.Res_1589_105
PubMedSearch : Shao_2014_Brain.Res_1589_105
PubMedID: 25281804

Title : Effect of tanshinone on the levels of nitric oxide synthase and acetylcholinesterase in the brain of Alzheimer's disease rat model - Yin_2008_Clin.Invest.Med_31_E248
Author(s) : Yin Y , Huang L , Liu Y , Huang S , Zhuang J , Chen X , Zhang L , Wu H , Shao F , Zhao Z
Ref : Clinical Investigation Med , 31 :E248 , 2008
Abstract : Yin_2008_Clin.Invest.Med_31_E248
ESTHER : Yin_2008_Clin.Invest.Med_31_E248
PubMedSearch : Yin_2008_Clin.Invest.Med_31_E248
PubMedID: 18980714